Vav Life Sciences, a little known nanotech research company, made an “accidental” entry into making specialised lipids used in targeted drug delivery. This has put the company in a small circle of just four global players making phospholipids, for mRNA vaccines.

Vav Life Sciences' Managing Director Arun Kedia explains the significance of targeted drug delivery, which is hailed as the medicine of tomorrow. The “silver bullet” or “sniper” approach helps deliver the medicine to the precise diseased cell.  

Edited by Gitanjali Diwakar